Skip to main content

Table 3 Adverse events during the adjuvant treatment phases. Values are expressed as numbers (percentage). Table presents grade I to IV adverse events in all patients during the adjuvant treatment phases. Adverse events are listed in descending order of frequency in the total patient population

From: Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

 Adjuvant chemo + CHMF (N = 114) n (%)Adjuvant chemo+ Placebo (N = 115) n (%)
Grade 1/2Grade 3/4TotalGrade 1/2Grade 3/4Total
Fatigue90 (78.9%)1 (0.8%)91 (79.7%)89 (77.45%)089 (77.45%)
Loss of appetite88 (77.2%)088 (77.2%)94 (81.7%)094 (81.7%)
Nausea77 (67.5%)1 (0.8%)78 (68.3%)77 (67%)077 (67%)
Leucopenia49 (43.6%)8 (7%)57 (50.6%)40 (34.8%)15 (13%)55 (47.8%)
Vomiting43 (37.3%)6 (4.4%)49 (41.7%)47 (40.9%)1 (0.8%)48 (41.7%)
Elevated TB37 (32.5%)1 (0.8%)38 (33.3%)40 (34.8%)040 (34.8%)
Constipation37 (32.5%)1 (0.8%)38 (33.3%)39 (33.9%)039 (33.9%)
Neutropenia34 (29.8%)11 (9.7%)45 (39.5%)37 (32.2%)17 (14.8%)54 (47%)
Anaemia29 (25.4%)029 (25.4%)28 (24.3%)1 (0.8%)29 (25.1%)
Dry mouth28 (24.6%)028 (24.6%)45 (39.1%)045 (39.1%)
Pain28 (24.7%)028 (24.7%)37 (32.2%)037 (32.2%)
Alopecia13 (11.4%)013 (11.4%)14 (12.2%)014 (12.2%)
ALT/AST increased12 (10.5%)1 (0.8%)13 (11.3%)15 (11.3%)015 (11.3%)
Elevated GGT11 (9.6%)2 (1.8%)13 (11.4%)9 (7.8%)1 (0.8%)10 (8.6%)
Diarrhoea9 (7.9%)09 (7.9%)20 (17.4%)020 (17.4%)
Thrombocytopaenia6 (5.3%)06 (5.3%)15 (13%)1 (0.8%)16 (13.8%)
Elevated CRE4 (3.5%)04 (3.5%)1 (0.9%)01 (0.9%)
Weight-decrease4 (3.5%)04 (3.5%)7 (6.1%)07 (6.1%)
Rash3 (2.6%)03 (2.6%)2 (1.7%)02 (1.7%)
Arhythmia2 (1.8%)02 (1.8%)2 (1.7%)1 (0.8%)3 (2.5%)
Pruritus2 (1.8%)02 (1.8%)4 (3.5%)04 (3.5%)
Elevated ALP1 (0.8%)01 (0.8%)1 (0.9%)01 (0.9%)